Optimum's Investor Conference Highlights Life Science's Feel Good Factor for 2025

31/10/2024

Optimism has well and truly returned to life sciences and this newfound confidence was reflected in many of the discussions at this year’s Optimum Strategic Communications Healthcare Investor Conference. 

Held at the prestigious King’s Fund venue in central London, the great and good of the biotech and pharma industry met to reflect on the events of 2024 and look forward to 2025 and beyond. 

The conference began with a discussion about biotech IPOs – which were hardly seen in the dark days of 2023, but which are now becoming increasingly common. 

One of the highlights of the conference was Scott’s fireside chat with Dr Daniel Mahony , senior partner at Novo Holdings, Growth Investments, where these two biotech influencers discussed how to accelerate innovation. 

According to Scott, Europe is an amazing place to find talented biotechs and entrepreneurs because of its diverse innovation talent, with huge potential for scientific breakthroughs, and also preventive health systems, in place because of state-funded healthcare systems such as the NHS. 

The European approach to healthcare could be very different from that in the U.S.  The value and impact of innovation is driven by understanding disease risk, delivering prevention and early interception to prevent people from getting ill, or delivering cures in earlier (more treatable) stages of disease presentation. This has the potential to generate better patient outcomes and drive GDP growth. 

Diseases of old age are hugely costly, when patients are more likely to develop co-morbidities that place a burden on the patient, their families, and the healthcare system. 

Read more about this fascinating topic by clicking the link below